A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial

被引：0

作者：

Annika Karch

Armin Koch

Viktor Grünwald

机构：

[1] Institute for Biostatistics,

[2] Hannover Medical School,undefined

[3] Clinic for Hematology,undefined

[4] Hemostasis,undefined

[5] Oncology and Stem Cell Transplantation,undefined

[6] Hannover Medical School,undefined

来源：

Trials | / 17卷

关键词：

Soft tissue sarcoma; Elderly; Doxorubicin; Pazopanib; Noninferiority;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 20 条

[1]

Jemal A(2010)Cancer statistics, 2010 CA Cancer J Clin. 60 277-300

[2]

Siegel R(2014)Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 25 iii102-12

[3]

Xu J(2011)Systematic therapy for unresectable or metastatic soft-tissue sarcomas: past, present, and future Curr Oncol Rep 13 331-49

[4]

Ward E(2002)Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas Eur J Cancer. 38 543-9

[5]

Morgan SS(2010)CONSORT 2010 Lancet 375 1136-60

[6]

Cranmer LD(2006)Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement JAMA. 295 1152-61

[7]

Van Glabbeke M(2008)Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma Expert Opin Investig Drugs. 17 253-undefined

[8]

Verweij J(undefined)undefined undefined undefined undefined-undefined

[9]

Judson I(undefined)undefined undefined undefined undefined-undefined

[10]

Nielsen OS(undefined)undefined undefined undefined undefined-undefined

← 1 2 →